Sign in

    Greg Wiesner

    Managing Director and Senior Equity Research Analyst at TD Cowen

    Greg Wiesner is a Managing Director and Senior Equity Research Analyst at TD Cowen, specializing in coverage of the healthcare and life sciences sectors with a particular focus on companies such as Cardinal Health, Owens & Minor, McKesson, and AmerisourceBergen. Over his career, Wiesner has earned strong performance metrics including high rankings on analyst platforms like TipRanks, where he is noted for his accurate and high-return stock recommendations. Having joined TD Cowen in 2022, he previously held analyst roles at firms including Wells Fargo, Jefferies, and BMO Capital Markets, building a track record recognized for both breadth and depth of sector expertise. Wiesner maintains professional credentials such as FINRA registration and holds multiple securities licenses reflecting his commitment to regulatory standards and industry best practices.

    Greg Wiesner's questions to Travere Therapeutics (TVTX) leadership

    Greg Wiesner's questions to Travere Therapeutics (TVTX) leadership • Q3 2024

    Question

    Greg Wiesner from TD Cowen requested insight into what Travere plans to propose during its Type C meeting with the FDA for sparsentan in FSGS and what key questions the company intends to ask the agency.

    Answer

    SVP of Research and Development Dr. Bill Rote explained that the company will leverage discussions from the PARASOL initiative and propose a proteinuria reduction threshold, likely around the 0.7 gram/gram/day level the FDA has mentioned. The key question for the FDA will be to clarify what additional data or analyses are needed for the submission to ensure full alignment for their review.

    Ask Fintool Equity Research AI